

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

華康生物醫學控股有限公司

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 8622)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 17 JUNE 2022

Reference is made to the notice of annual general meeting (the “AGM Notice”) of Huakang Biomedical Holdings Company Limited (the “Company”) and the circular of the Company dated 13 May 2022 (the “Circular”). Unless otherwise specified herein, capitalised terms used herein shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE ANNUAL GENERAL MEETING (THE “AGM”)

The Board is pleased to announce that the proposed ordinary resolutions (the “Resolutions”) as set out in the AGM Notice were duly passed by the Shareholders by way of poll at the AGM held on 17 June 2022.

The poll results in respect of the Resolutions proposed at the AGM are as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive and approve the audited consolidated financial statements of the Company and the reports of the directors and auditor for the year ended 31 December 2021.	258,976,000 (100%)	0 (0%)
2(a).	To re-elect Mr. Zhang Shuguang as an executive director of the Company.	258,976,000 (100%)	0 (0%)
2(b).	To re-elect Mr. Zhang Chunguang as an executive director of the Company.	258,976,000 (100%)	0 (0%)
2(c).	To re-elect Dr. Cheng Faat Ting Gary as an independent non-executive director of the Company.	258,976,000 (100%)	0 (0%)
3.	To authorize the board of directors of the Company to fix the respective directors’ remuneration.	258,976,000 (100%)	0 (0%)

4.	To re-appoint Mazars CPA Limited as auditor of the Company and to authorize the board of directors to fix their remuneration.	258,976,000 (100%)	0 (0%)
5.	To give a general and unconditional mandate to the directors to buy back shares of the Company not exceeding 10% of the total number of issued shares of the Company as at the date of passing of this resolution.	258,976,000 (100%)	0 (0%)
6.	To give a general and unconditional mandate to the directors to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company as at the date of passing of this resolution.	258,976,000 (100%)	0 (0%)
7.	To extend the general and unconditional mandate granted to the directors under resolution number (6) above to issue, allot and deal with additional shares in the capital of the Company by the aggregate number of the shares to be bought back by the Company under resolution number (5) above.	258,976,000 (100%)	0 (0%)

Notes:

- (a) As all of the votes were cast in favour of each of the resolutions numbered 1 to 7, all resolutions were duly passed as ordinary resolutions.
- (b) As at the date of the AGM, the total number of shares of the Company in issue was 400,000,000 shares.
- (c) The total number of shares of the Company in issue entitling the holder to attend and vote on the resolutions at the AGM was 400,000,000 shares.
- (d) There were no shares entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 17.47A of the Rules Governing the Listing of Securities on the GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”).
- (e) No shareholder of the Company was required under the GEM Listing Rules to abstain from voting on the resolutions at the AGM.
- (f) None of the shareholders of the Company have stated their intention in the Company’s circular dated 13 May 2022 to vote against or to abstain from voting on any of the resolutions at the AGM.
- (g) The Company’s branch share registrar, Tricor Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.

By Order of the Board
Huakang Biomedical Holdings Company Limited
Zhang Shuguang
Chairman and Executive Director

Hong Kong, 17 June 2022

As at the date of this announcement, the Executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Mr. He Jiaming; and the Independent Non-executive Directors are Dr. Chow Kwok Fai Joseph, Dr. Cheng Faat Ting Gary and Mr. Chan Kin Sang.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the Stock Exchange website at www.hkexnews.hk for at least seven days from the date of publication and on the Company’s website at www.huakangbiomedical.com.